HPV Antibodies and Survival in Head and Neck Cancer
Author Information
Author(s): Linda M Rubenstein, Elaine M Smith, Michael Pawlita, Thomas H Haugen, Eva Hamšíková, Lubomir P Turek
Primary Institution: University of Iowa
Hypothesis
Are antibody levels to HPV-16 E6 and E7 associated with head and neck cancer risk factors or prognosis?
Conclusion
HPV antibodies may serve as potential prognostic markers of survival in head and neck cancer patients.
Supporting Evidence
- HPV-16 E6 and/or E7 seropositive cases had worse outcomes.
- Younger patients and those with more sexual partners were more likely to be seropositive.
- Overall mortality was significantly worse among seronegative patients.
Takeaway
This study found that patients with certain HPV antibodies had better survival rates, suggesting these antibodies could help doctors predict how well patients will do.
Methodology
Antibody levels were measured in blood samples from newly diagnosed head and neck cancer patients using ELISA.
Potential Biases
Potential biases may arise from the correlation between treatment types and seropositivity.
Limitations
The study was limited to a specific patient population and may not be generalizable to all head and neck cancer patients.
Participant Demographics
The majority of participants were male (61%) with an average age of 59 years.
Statistical Information
P-Value
p = 0.01
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website